Optimization of Mesenchymal Stromal Cell (MSC) Manufacturing Processes for a Better Therapeutic Outcome
Open accessThe DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
MSCs products as well as their derived extracellular vesicles, are currently being explored as advanced biologics in cell-based therapies with high expectations for their clinical use in the next few years. In recent years, various strategies designed for improving the therapeutic potential of mesenchymal stromal cells (MSCs), including pre-conditioning for enhanced cytokine production, improved cell homing and strengthening of immunomodulatory properties, have been developed but the manufacture and handling of these cells for their use as advanced therapy medicinal products (ATMPs) remains insufficiently studied, and available data are mainly related to non-industrial processes. In the present article, we will review this topic, analyzing current information on the specific regulations, the selection of living donors as well as MSCs from different sources (bone marrow, adipose tissue, umbilical cord, etc.), in-process quality controls for ensuring cell efficiency and safety during all stages of the manual and automatic (bioreactors) manufacturing process, including cryopreservation, the use of cell banks, handling medicines, transport systems of ATMPs, among other related aspects, according to European and US legislation. Our aim is to provide a guide for a better, homogeneous manufacturing of therapeutic cellular products with special reference to MSCs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dominici, M., Le Blanc, K., Mueller, I., Slaper-Cortenbach, I., Marini, F. C., Krause, D. S., Deans, R. J., Keating, A., Prockop, D. J., & Horwitz, E. M. (2006) · Cytotherapy · doi:10.1080/14653240600855905 · Cited by 17,766
Extracellular vesicles: Exosomes, microvesicles, and friends
Raposo, G., & Stoorvogel, W. (2013) · Journal of Cell Biology · doi:10.1083/jcb.201211138 · Cited by 8,099 · cited 1×
“Among them, exosomes, also known as small extracellular vesicles (EVs), are nanosized vesicles released by almost all cell types across species (91).”
BackgroundKern, S., Eichler, H., Stoeve, J., Klüter, H., & Bieback, K. (2006) · STEM CELLS · doi:10.1634/stemcells.2005-0342 · Cited by 3,370
Delivery materials for siRNA therapeutics
Kanasty, R., Dorkin, J. R., Vegas, A., & Anderson, D. (2013) · Nature Materials · doi:10.1038/nmat3765 · Cited by 1,800
Kojima, R., Bojar, D., Rizzi, G., Hamri, G. C.-E., El-Baba, M. D., Saxena, P., Ausländer, S., Tan, K. R., & Fussenegger, M. (2018) · Nature Communications · doi:10.1038/s41467-018-03733-8 · Cited by 748 · cited 1×
“This can be achieved either by modification of the biosynthetic pathway (106) or by stress signals like radiation, oxidative stress or hypoxia, with the latter being the most commonly used (94, 107, 108).”
MethodChoudhery, M. S., Badowski, M., Muise, A., Pierce, J., & Harris, D. T. (2014) · Journal of Translational Medicine · doi:10.1186/1479-5876-12-8 · Cited by 529
Han, Y., Ren, J., Bai, Y., Pei, X., & Han, Y. (2019) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2019.01.017 · Cited by 320 · cited 1×
“Indeed, many investigations have tried to mimic the pathologic environment by conditioning MSCs with proinflammatory cocktails (109), low oxygen concentration (110), or HIF1-a overexpression (111, 112).”
BackgroundAging alters tissue resident mesenchymal stem cell properties
Alt, E. U., Senst, C., Murthy, S. N., Slakey, D. P., Dupin, C. L., Chaffin, A. E., Kadowitz, P. J., & Izadpanah, R. (2012) · Stem Cell Research · doi:10.1016/j.scr.2011.11.002 · Cited by 316
Xu, L., Liu, Y., Sun, Y., Wang, B., Xiong, Y., Lin, W., Wei, Q., Wang, H., He, W., Wang, B., et al. (2017) · Stem Cell Research & Therapy · doi:10.1186/s13287-017-0716-x · Cited by 284
A consensus introduction to serum replacements and serum‐free media for cellular therapies
Karnieli, O., Friedner, O. M., Allickson, J. G., Zhang, N., Jung, S., Fiorentini, D., Abraham, E., Eaker, S. S., Yong, T. K., Chan, A., et al. (2017) · Cytotherapy · doi:10.1016/j.jcyt.2016.11.011 · Cited by 234
Cited by
Advancements and Challenges in Stem Cell Transplantation for Regenerative Medicine
Wei, L., Yan, W., Shah, W., Zhang, Z., Wang, M., Liu, B., Xue, Z., Cao, Y., Hou, X., Zhang, K., et al. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e35836 · Cited by 79
“This includes developing standardized protocols for MSC isolation, expansion, and characterization, as well as exploring novel delivery methods and biomaterial scaffolds to enhance the therapeutic efficacy of MSCs [143].”
MethodManufacturing cell and gene therapies: challenges in clinical translation
Lee, N. K., & Chang, J. W. (2024) · Annals of Laboratory Medicine · doi:10.3343/alm.2023.0382 · Cited by 78
“Although numerous autologous stem cell transplantations have been performed for MSC therapy, allogeneic cells have been predominantly used for that purpose [11, 12].”
BackgroundMesenchymal Stromal Cells for Aging Cartilage Regeneration: A Review
Wu, K.-C., Chang, Y.-H., Ding, D.-C., & Lin, S.-Z. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252312911 · Cited by 33
“This personalized approach enables for optimization of MSC source (whether autologous or allogeneic), dosage, and potential combination with other therapies, such as growth factors or drugs, ensuring that the therapy is best suited to the individual’s condition [197,198].”
Sheikhi, K., Ghaderi, S., Firouzi, H., Rahimibarghani, S., Shabani, E., Afkhami, H., & Yarahmadi, A. (2025) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2025.1517369 · Cited by 20
Mamo, T., Cox, C. A., Demorest, C., Fontaine, M. J., Hubel, A., Kelley, L., Khan, A., Marks, D. C., Pati, S., Reems, J.-A., et al. (2024) · Cytotherapy · doi:10.1016/j.jcyt.2024.07.001 · Cited by 16
Metadata
- Authors
- Fernández-Santos, M. E., Garcia-Arranz, M., Andreu, E. J., García-Hernández, A. M., López-Parra, M., Villarón, E., Sepúlveda, P., Fernández-Avilés, F., García-Olmo, D., Prosper, F., Sánchez-Guijo, F., Moraleda, J. M., & Zapata, A. G.
- Venue
- Frontiers in Immunology
- Publisher
- Frontiers Media SA
- Published
- 2022-06-09
- Volume
- 13
- Pages
- 918565-918565
- ISSN
- 1664-3224 (ISSN-L)
- OpenAlex
- W4281644643
- Cited by
- 139
- References
- 16
- FWCI
- 13.10
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Optimization of Mesenchymal Stromal Cell (MSC) Manufacturing Processes for a Better Therapeutic Outcome. https://app.cochat.ai/papers/10.3389/fimmu.2022.918565
- The paper
- Fernández-Santos, M. E., Garcia-Arranz, M., Andreu, E. J., García-Hernández, A. M., López-Parra, M., Villarón, E., Sepúlveda, P., Fernández-Avilés, F., García-Olmo, D., Prosper, F., Sánchez-Guijo, F., Moraleda, J. M., & Zapata, A. G. (2022). Optimization of Mesenchymal Stromal Cell (MSC) Manufacturing Processes for a Better Therapeutic Outcome. Frontiers in Immunology. https://doi.org/10.3389/fimmu.2022.918565
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.